Searched for
BROMSITE
Tildra approval to give sentimental push to Sun PharmaThe drug which will be sold under the brand name Ilumya is expected to treat adults for moderate to severe plaque psoriasis, an autoimmune ...22 Mar, 2018, 09.24 AM IST- USFDA accepts Sun Pharma arm's ophthalmic drug applicationSun Pharma said that post the USFDA approval, OTX-101 will be commercialised in the US by Sun Ophthalmics, the branded ophthalmics division...27 Dec, 2017, 11.50 AM IST
- Sun Pharma hits 44-month low, down 24% in 7 sessions; what experts sayThe stock fell 12.84 per cent to hit a 44-month low of Rs 495.55 amid weak fourth quarter results.29 May, 2017, 10.17 AM IST
- Sun Pharma Q3 net profit slips 4.7% YoY to Rs 1,471.82 croreSales for the quarter came in at Rs 7,683.24 crore, compared with Rs 7,087.07 crore in the same quarter last year.15 Feb, 2017, 12.44 AM IST
- How top Indian drug makers like Sun Pharma, Glenmark are building a brands business in the USWhile the market opportunities to sell brands appear optimistic, that road is less treaded by Indian companies and obvious challenges can l...07 Jan, 2017, 12.43 AM IST
- Fourteen stocks in focus on Tuesday, 29 November 2016Sun Pharma launched BromSite solution, marked for treatment of postoperative inflammation and prevention of ocular pain in patients undergo...29 Nov, 2016, 08.43 AM IST
- Sun Pharma launches first branded drug BromSite in USThe launch marks Sun Pharma’s entry into the branded drugs business in the US, a segment that many generic drug companies are targeting as ...28 Nov, 2016, 08.43 PM IST
- Sun Pharma to buy Ocular Technologies from Auven TherapeuticsSun will pay Auven $40 million upfront, contingent development milestones and sales milestones, in addition to royalties on sales of Secier...27 Oct, 2016, 11.27 AM IST
- Fy17 forecast: Sun Pharma expects 8-10 per cent sales growthThe company, which made windfall gains in the fourth quarter from sales of cancer drug imatinib in the US, said it will invest up to 9% of ...01 Jun, 2016, 04.18 AM IST
- Sun Pharma guides 8% to 10% sales growth for FY17For the full year, Sun notched up net sales/total income of Rs 27744 crore, growing 2% over the corresponding year last year.31 May, 2016, 01.15 PM IST
- Sun Pharma gains on USFDA nod for eyecare drug BromSiteCountry’s biggest pharma company's shares surget up to 2% today. Sun Pharma received the USFDA nod to sell eyecare drug BromSite in the Uni...11 Apr, 2016, 04.26 PM IST
- TRACK SENSEX, NIFTY LIVE: Who moved my market todayIf you are reading this, chances are Sensex and Nifty are part of your daily life, and actions on Dalal Street can make or mar your day. He...11 Apr, 2016, 04.07 PM IST
- Fifteen stocks in focus in Monday morning tradeThe Indian market is expected to open flat on Monday tracking muted trend seen in other Asian markets.11 Apr, 2016, 07.56 AM IST
- USFDA nod for eyecare drug BromSite gives boost to Sun PharmaThe product will be commercialized through New Jersey-based Sun Ophthalmics, a division that Sun formed recently to route its specialty bra...11 Apr, 2016, 01.59 AM IST
- Sun Pharma gets USFDA nod for eye inflammation drugThe company is likely to commercialise BromSite through its newly formed US-based division Sun Ophthalmics in the second half of 2016.10 Apr, 2016, 01.45 PM IST
- Dilip Shanghvi's Sun pharma sets sights on InSite Vision of US; deal may be valued at about Rs 300 croreSun Pharmaceutical Industries has bid to acquire US eye care company InSite Vision to expand its basket of specialty products and boost sal...16 Sep, 2015, 05.05 PM IST
- Sun Pharma bids to acquire InSite Vision IncSources close to the transaction have indicated that Sun Pharma has already bid for US OTC Market listed Insite Vision for Rs 300 cr.15 Sep, 2015, 01.56 PM IST
Load More
